AtriCure, Inc. engages in the development, manufacture, and sale of surgical ablation of cardiac tissue, and systems for the exclusion of the left atrial appendage. Its products include radio frequency (RF) ablation pacing and sensing, cryo, left atrial appendage management, soft tissue dissection, estech surgical instrumentation, and cart configuration. It operates through the following geographical segments: United States, Europe, Asia, and Other International. The company was founded in 1994 and is headquartered in Mason, OH.
Current Value
$31.501 Year Return
Current Value
$31.501 Year Return
Market Cap
$1.61B
P/E Ratio
-34.59
1Y Stock Return
25.89%
1Y Revenue Growth
16.55%
Dividend Yield
0.00%
Price to Book
3.5
Double maintains 1 strategies that include ATRC - AtriCure, Inc.
Medium risk
$14.0K
This Strategy focuses on healthcare companies, including pharmaceuticals, biotechnology, healthcare providers, and medical equipment firms. Offering exposure to a sector driven by demographic trends and ongoing medical advancements, it's a strategic choice for investors considering healthcare's long-term growth potential.
Top Sector
Health Care
Top Holdings
Bktd. Return
Expense Ratio
0.00%
Holdings
346
The stocks that are correlated to ATRC - AtriCure, Inc. are SW, SMP, GHC, BRSP, ENOV
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
47.66% | $22.29B | -7.59% | 2.55% | |
47.54% | $522.50M | -27.93% | 5.08% | |
44.10% | $4.12B | +25.33% | 0.76% | |
43.94% | $706.86M | -16.90% | 12.95% | |
E ENOVEnovis Corp. | 43.91% | $1.92B | -43.41% | 0.00% |
N NRDSNerdWallet, Inc. | 41.26% | $636.59M | -37.75% | 0.00% |
39.20% | $162.20B | +5.63% | 3.12% | |
39.12% | $1.70B | +19.70% | 2.12% | |
P PRAAPRA Group, Inc. | 38.68% | $809.55M | -19.11% | 0.00% |
I IEXIDEX Corp. | 38.37% | $12.74B | -28.76% | 1.69% |
S SCLStepan Co. | 38.23% | $1.12B | -42.94% | 3.13% |
G GRMNGarmin Ltd. | 37.67% | $35.66B | +27.91% | 1.68% |
37.43% | $1.33B | +6.73% | 3.20% | |
37.31% | $1.54B | +3.84% | 0.00% | |
37.13% | $2.77B | -21.39% | 0.00% | |
37.06% | $362.22M | -44.90% | 0.00% | |
36.81% | $5.34B | -8.00% | 9.81% | |
36.77% | $2.02B | -1.34% | 2.99% | |
D DASHDoorDash, Inc. | 36.61% | $73.09B | +29.25% | 0.00% |
36.54% | $2.38B | +48.62% | 0.00% |
The ETFs that are correlated to ATRC - AtriCure, Inc. are XHE, BTC, IHI, CPRJ, GSSC
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
48.41% | $176.51M | 0.35% | |
45.23% | $3.28B | 0.15% | |
41.39% | $4.63B | 0.4% | |
40.48% | $48.65M | 0.69% | |
37.66% | $521.56M | 0.2% | |
37.45% | $2.38B | 0.39% | |
37.34% | $842.66M | 0.6% | |
37.23% | $582.47M | 0.38% | |
36.99% | $320.39M | 0.79% | |
36.81% | $11.17B | 0.03% | |
36.68% | $79.87B | 0.06% | |
36.68% | $2.79B | 0.07% | |
36.63% | $63.84B | 0.19% | |
36.60% | $3.79B | 0.15% | |
36.54% | $6.49B | 0.18% | |
36.47% | $11.24B | 0.07% | |
36.46% | $680.46M | 0.4% | |
36.20% | $1.24B | 0.1% | |
36.15% | $964.24M | 0.62% | |
36.14% | $11.04B | 0.24% |
Yahoo
MASON, Ohio, March 12, 2025--AtriCure, Inc. (Nasdaq: ATRC), a leading innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, today reaffirmed that the company will host an Analyst & Investor Day at its headquarters in Mason, Ohio on Wednesday, March 26, 2025 from 1:00 pm to 4:00 pm ET.
Yahoo
AtriCure ( NASDAQ:ATRC ) Full Year 2024 Results Key Financial Results Revenue: US$465.3m (up 17% from FY 2023). Net...
Yahoo
Q4 2024 AtriCure Inc Earnings Call
Yahoo
Here is how AnaptysBio, Inc. (ANAB) and AtriCure (ATRC) have performed compared to their sector so far this year.
Yahoo
AtriCure Inc (ATRC) reports a 17% revenue increase in 2024, driven by new product launches and robust international sales, despite challenges in gross margin and R&D expenses.
SeekingAlpha
AtriCure, Inc. (NASDAQ:ATRC) Q4 2024 Earnings Conference Call February 12, 2025 4:30 PM ETCompany ParticipantsMarissa Bych - Investor RelationsMichael...
Information on this page is obtained from our data provider, Xignite, an unaffiliated third party. Double believes the information shown here is reliable, but has not been verified and there is no guarantee that the information is accurate. We also show information based on calculations performed by Double using data from our provider. Double believes this information is reliable, but has not verified the data and there is no guarantee that the calculations are accurate.
We offer over 50 indexes with zero expense ratios.
Registration will take about 10 seconds